Metabolic syndrome and colorectal cancer: Is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process?

Journal of Geriatric Oncology

Volumn 5, Issue 1, 2014, Pages 40-48

  Liu, Jane Jijun ^a   Druta, Mihaela ^a   Shibata, David ^a   Coppola, Domenico ^a   Boler, Ivette ^a   Elahi, Abul ^a   Reich, Richard R ^a,b   Siegel, Erin ^a   Extermann, Martine ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA SARASOTA MANATEE   (United States)

Author keywords

Colorectal cancer; Elderly; Hyperinsulinemia; IGF 1; Insulin receptor; Metabolic syndrome; Tumor vasculature

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; INSULIN; INSULIN RECEPTOR; INTERLEUKIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION; VERY ELDERLY;

COLORECTAL CANCER; ELDERLY; HYPERINSULINEMIA; IGF-1; INSULIN RECEPTOR; METABOLIC SYNDROME; TUMOR VASCULATURE;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPERINSULINISM; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84893664603     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2013.11.004     Document Type: Article

References (40)

1. Yancik R., Havlik R.J., Wesley M.N., Ries L., Long S., Rossi W.K., et al. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol 1996, 6(5):399-412. [Epub 1996/09/01].
2. Yancik R., Wesley M.N., Ries L.A., Havlik R.J., Long S., Edwards B.K., et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998, 82(11):2123-2134. [Epub 1998/06/04].
3. Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998, 16(4):1582-1587.
4. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287(3):356-359. [Epub 2002/01/16].
5. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15(7):539-553.
6. Kabat G.C., Kim M.Y., Peters U., Stefanick M., Hou L., Wactawski-Wende J., et al. A longitudinal study of the metabolic syndrome and risk of colorectal cancer in postmenopausal women. Eur J Cancer Prev 2012, 21(4):326-332. [Epub 2011/11/03].
7. Shen Z., Ye Y., Bin L., Yin M., Yang X., Jiang K., et al. Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis. Am J Surg 2010, 200(1):59-63. [Epub 2010/01/16].
8. Stocks T., Lukanova A., Bjorge T., Ulmer H., Manjer J., Almquist M., et al. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer 2011 Jun 1, 117(11):2398-2407. [Epub 2010/12/21].
9. Meyerhardt J.A., Tepper J.E., Niedzwiecki D., Hollis D.R., McCollum A.D., Brady D., et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 2004, 22(4):648-657. [Epub 2004/02/18].
10. Yamada K., Araki S., Tamura M., Sakai I., Takahashi Y., Kashihara H., et al. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol 1998, 27(5):794-798. [Epub 1998/12/05].
11. Colangelo L.A., Gapstur S.M., Gann P.H., Dyer A.R., Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2002, 11(4):385-391. [Epub 2002/04/03].
12. Hakam A., Yeatman T.J., Lu L., Mora L., Marcet G., Nicosia S.V., et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999, 30(10):1128-1133. [Epub 1999/10/26].
13. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342. [Epub 2004/06/04].
14. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004, 292(12):1440-1446. [Epub 2004/09/24].
15. Lee Y.H., Pratley R.E. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005, 5(1):70-75. [Epub 2005/01/25].
16. Kuniyasu H., Sasaki T., Sasahira T., Ohmori H., Takahashi T. Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 2004, 71(3):129-136. [Epub 2004/03/31].
17. Kuniyasu H., Chihara Y., Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003, 10(2):445-448. [Epub 2003/02/13].
18. Levy J.C., Matthews D.R., Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21(12):2191-2192. [Epub 1998/12/05].
19. Allred D.C., Harvey J.M., Berardo M., Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11(2):155-168. [Epub 1998/03/21].
20. Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens C.H., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999, 91(7):620-625. [Epub 1999/04/15].
21. Dunn S.E., Kari F.W., French J., Leininger J.R., Travlos G., Wilson R., et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997, 57(21):4667-4672. [Epub 1997/11/14].
22. Makino T., Noguchi Y., Yoshikawa T., Doi C., Nomura K. Circulating interleukin 6 concentrations and insulin resistance in patients with cancer. Br J Surg 1998, 85(12):1658-1662. [Epub 1999/01/06].
23. Belluco C., Nitti D., Frantz M., Toppan P., Basso D., Plebani M., et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 2000, 7(2):133-138. [Epub 2000/04/13].
24. Hu F.B., Manson J.E., Liu S., Hunter D., Colditz G.A., Michels K.B., et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999, 91(6):542-547. [Epub 1999/03/24].
25. Rechler M.M. Growth inhibition by insulin-like growth factor (IGF) binding protein-3-what's IGF got to do with it?. Endocrinology 1997, 138(7):2645-2647. [Epub 1997/07/01].
26. Dy D.Y., Whitehead R.H., Morris D.L. SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res 1992, 52(4):917-923.
27. Pollak M.N., Polychronakos C., Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 1989, 9(4):889-891. [Epub 1989/07/01].
28. Yang Y.X., Hennessy S., Lewis J.D. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004, 127(4):1044-1050. [Epub 2004/10/14].
29. Lee W.M., Lu S., Medline A., Archer M.C. Susceptibility of lean and obese Zucker rats to tumorigenesis induced by N-methyl-N-nitrosourea. Cancer Lett 2001, 162(2):155-160. [Epub 2001/01/09].
30. Zhu S., Patel K.V., Bandinelli S., Ferrucci L., Guralnik J.M. Predictors of interleukin-6 elevation in older adults. J Am Geriatr Soc 2009, 57(9):1672-1677. [Epub 2009/08/22].
31. Zuliani G., Galvani M., Maggio M., Volpato S., Bandinelli S., Corsi A.M., et al. Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance. Atherosclerosis 2010, 213(1):319-324. [Epub 2010/09/28].
32. Choi K.M., Lee J., Lee K.W., Seo J.A., Oh J.H., Kim S.G., et al. Comparison of serum concentrations of C-reactive protein, TNF-alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract 2004, 64(2):99-106. [Epub 2004/04/06].
33. Voss M.W., Erickson K.I., Prakash R.S., Chaddock L., Kim J.S., Alves H., et al. Neurobiological markers of exercise-related brain plasticity in older adults. Brain Behav Immun 2013, 28:90-99. [Epub 2012/11/06].
34. Rensing K.L., Houttuijn Bloemendaal F.M., Weijers E.M., Richel D.J., Buller H.R., Koolwijk P., et al. Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis?. Diabetologia 2010, 53(5):966-970. [Epub 2010/02/26].
35. Liu Y., Petreaca M., Martins-Green M. Cell and molecular mechanisms of insulin-induced angiogenesis. J Cell Mol Med 2009, 13(11-12):4492-4504. [Epub 2009/07/16].
36. Zhang H., Fagan D.H., Zeng X., Freeman K.T., Sachdev D., Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010, 29(17):2517-2527. [Epub 2010/02/16].
37. Jassem J., Langer C.J., Karp D.D., Mok T., Benner R.J., Green S.J., et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(15s). [Suppl.; abstr 7500].
38. Huang F., Hurlburt W., Greer A., Reeves K.A., Hillerman S., Chang H., et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 2010, 70(18):7221-7231. [Epub 2010/09/03].
39. Carboni J.M., Wittman M., Yang Z., Lee F., Greer A., Hurlburt W., et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009, 8(12):3341-3349. [Epub 2009/12/10].
40. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310(6972):83-88. [Epub 1995/01/14].